Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists

IF 6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Giuseppe Lisco, Anna De Tullio, Olga Eugenia Disoteo, Michela Armigliato, Edoardo Guastamacchia, Simonetta Marucci, Giovanni De Pergola, Enrico Papini, Marco Chianelli, Andrea Frasoldati, Vincenzo De Geronimo, Vincenzo Triggiani, The Italian Association of Clinical Endocrinologists—Medications and Therapeutics Committee; Diabetes Committee; Obesity and Eating Disorders Committee; Technology, Telehealth, and Digital Innovation Committee
{"title":"Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists","authors":"Giuseppe Lisco,&nbsp;Anna De Tullio,&nbsp;Olga Eugenia Disoteo,&nbsp;Michela Armigliato,&nbsp;Edoardo Guastamacchia,&nbsp;Simonetta Marucci,&nbsp;Giovanni De Pergola,&nbsp;Enrico Papini,&nbsp;Marco Chianelli,&nbsp;Andrea Frasoldati,&nbsp;Vincenzo De Geronimo,&nbsp;Vincenzo Triggiani,&nbsp;The Italian Association of Clinical Endocrinologists—Medications and Therapeutics Committee; Diabetes Committee; Obesity and Eating Disorders Committee; Technology, Telehealth, and Digital Innovation Committee","doi":"10.1002/dmrr.70073","DOIUrl":null,"url":null,"abstract":"<p>Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so-called ‘lean phenotype’ of diabetes. The sharp rise of weight excess and obesity-related cardio-nephron-metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and emerging dual agonists, especially while managing cardio-metabolic burdens, in T2D have encouraged fervent anecdotal and non-anecdotal research also in T1D, indicating that non-insulin injective agents can be effective and safe. With this expert opinion paper, the members of four of the most representative Committees of the Italian Association of Clinical Endocrinologists provide the scientific community with a state-of-the-art report on the use of GLP-1RAs and other incretin-based injective therapy to treat body weight excess in T1D individuals and new insights on the topic with reliable methodology and clinical expertise.</p>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 6","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70073","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so-called ‘lean phenotype’ of diabetes. The sharp rise of weight excess and obesity-related cardio-nephron-metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and emerging dual agonists, especially while managing cardio-metabolic burdens, in T2D have encouraged fervent anecdotal and non-anecdotal research also in T1D, indicating that non-insulin injective agents can be effective and safe. With this expert opinion paper, the members of four of the most representative Committees of the Italian Association of Clinical Endocrinologists provide the scientific community with a state-of-the-art report on the use of GLP-1RAs and other incretin-based injective therapy to treat body weight excess in T1D individuals and new insights on the topic with reliable methodology and clinical expertise.

Abstract Image

基于肠促胰岛素辅助背景胰岛素治疗管理体重超标1型糖尿病:来自意大利临床内分泌学家协会的专家意见观点
超重和肥胖是普通人群中常见的慢性代谢紊乱,观察到的趋势表明,在1型糖尿病(T1D)患者中,体重过量的患病率也在大幅增长,即糖尿病的“瘦表型”。在T2D中观察到的体重超重和肥胖相关的心脏肾代谢负担的急剧上升预计会在T1D中产生类似的后果,导致迫切需要批准治疗方案,因为在世界上大多数地区没有批准用于T1D的辅助治疗,这使得这些个体的体重超重管理具有挑战性。新的胰高血糖素样肽1受体激动剂(GLP-1RAs)和新兴的双重激动剂在T2D中的显著结果,特别是在管理心脏代谢负担时,鼓励了T1D的热切轶事和非轶事研究,表明非胰岛素注射药物可能是有效和安全的。在这篇专家意见论文中,意大利临床内分泌学家协会四个最具代表性委员会的成员为科学界提供了一份关于使用GLP-1RAs和其他基于肠促胰岛素的注射疗法治疗T1D患者体重过重的最新报告,并通过可靠的方法和临床专业知识对该主题提出了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes/Metabolism Research and Reviews
Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢
CiteScore
17.20
自引率
2.50%
发文量
84
审稿时长
4-8 weeks
期刊介绍: Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信